Precision Cancer Prevention Needs Both Implementation Science and Ethics
As technological and genomic innovations continue to advance precision cancer prevention, psychosocial, ethical, and operational complexities increasingly accompany their development. Addressing these challenges will require intentional cross-disciplinary collaboration. We argue that the distinct yet complementary lenses of bioethics and implementation science will be crucial as precision cancer prevention technologies move toward clinical integration. We provide a framework for how this joint effort can be accomplished and sustained across the translational pipeline.
Authors
- Steven W. Ressler (ORCID: https://orcid.org/0009-0009-7186-6593)
- Lila J. Finney Rutten (ORCID: https://orcid.org/0000-0001-7487-9407)
- Jon C. Tilburt (ORCID: https://orcid.org/0000-0001-6165-6415)
- Amanda Courtright-Lim (ORCID: https://orcid.org/0000-0003-2338-5508)
- Jessica D. Austin (ORCID: https://orcid.org/0000-0001-8286-7801)
- Alexandra Lauren Wicker (ORCID: https://orcid.org/0009-0005-8824-5241)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Oklahoma State University Oklahoma City (US)
- Mayo Clinic in Florida (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Cancer Prevention Research
- Published
- 2026-09-01
- DOI
- https://doi.org/10.1158/1940-6207.capr-26-0081
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00